These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 21504508

  • 21. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.
    Negishi K, Noiri E, Maeda R, Portilla D, Sugaya T, Fujita T.
    Kidney Int; 2008 Jun; 73(12):1374-84. PubMed ID: 18368030
    [Abstract] [Full Text] [Related]

  • 22. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.
    Mou S, Wang Q, Li J, Shi B, Ni Z.
    Clin Chim Acta; 2012 Jan 18; 413(1-2):187-91. PubMed ID: 21958699
    [Abstract] [Full Text] [Related]

  • 23. Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation.
    Ichikawa D, Kamijo-Ikemori A, Sugaya T, Shibagaki Y, Yasuda T, Katayama K, Hoshino S, Igarashi-Migitaka J, Hirata K, Kimura K.
    Am J Physiol Renal Physiol; 2014 Mar 15; 306(6):F655-63. PubMed ID: 24431207
    [Abstract] [Full Text] [Related]

  • 24. Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.
    Katayama M, Ohata K, Miyazaki T, Katayama R, Wakamatsu N, Ohno M, Yamashita T, Oikawa T, Sugaya T, Miyazaki M.
    J Vet Intern Med; 2020 Mar 15; 34(2):761-769. PubMed ID: 32087614
    [Abstract] [Full Text] [Related]

  • 25. Characterization of critical factors influencing gene expression of two types of fatty acid-binding proteins (L-FABP and Lb-FABP) in the liver of birds.
    Murai A, Furuse M, Kitaguchi K, Kusumoto K, Nakanishi Y, Kobayashi M, Horio F.
    Comp Biochem Physiol A Mol Integr Physiol; 2009 Oct 15; 154(2):216-23. PubMed ID: 19540927
    [Abstract] [Full Text] [Related]

  • 26. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.
    Kanaguchi Y, Suzuki Y, Osaki K, Sugaya T, Horikoshi S, Tomino Y.
    Nephrol Dial Transplant; 2011 Nov 15; 26(11):3465-73. PubMed ID: 21525165
    [Abstract] [Full Text] [Related]

  • 27. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.
    Negishi K, Noiri E, Sugaya T, Li S, Megyesi J, Nagothu K, Portilla D.
    Kidney Int; 2007 Aug 15; 72(3):348-58. PubMed ID: 17495861
    [Abstract] [Full Text] [Related]

  • 28. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
    Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K.
    Am J Nephrol; 2006 Aug 15; 26(1):82-6. PubMed ID: 16534182
    [Abstract] [Full Text] [Related]

  • 29. L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules.
    Nakamura K, Ito K, Kato Y, Sugaya T, Kubo Y, Tsuji A.
    Drug Metab Pharmacokinet; 2008 Aug 15; 23(4):271-8. PubMed ID: 18762714
    [Abstract] [Full Text] [Related]

  • 30. L-FABP: A novel biomarker of kidney disease.
    Xu Y, Xie Y, Shao X, Ni Z, Mou S.
    Clin Chim Acta; 2015 May 20; 445():85-90. PubMed ID: 25797895
    [Abstract] [Full Text] [Related]

  • 31. Liver fatty acid binding protein gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice.
    Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F.
    Am J Physiol Gastrointest Liver Physiol; 2006 Jan 20; 290(1):G36-48. PubMed ID: 16123197
    [Abstract] [Full Text] [Related]

  • 32. Fatty acid-binding proteins as plasma markers of tissue injury.
    Pelsers MM, Hermens WT, Glatz JF.
    Clin Chim Acta; 2005 Feb 20; 352(1-2):15-35. PubMed ID: 15653098
    [Abstract] [Full Text] [Related]

  • 33. Liver-type fatty acid binding protein in serum and broncho-alveolar lavage in a model of acute respiratory failure because of surfactant depletion--a possible marker for lung damage?
    Lachmann RA, Werchan S, Schachtrup C, Haitsma JJ, Spener F, Lachmann B.
    Clin Physiol Funct Imaging; 2006 Nov 20; 26(6):371-5. PubMed ID: 17042904
    [Abstract] [Full Text] [Related]

  • 34. An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli.
    Velkov T, Chuang S, Prankerd R, Sakellaris H, Porter CJ, Scanlon MJ.
    Protein Expr Purif; 2005 Nov 20; 44(1):23-31. PubMed ID: 15914028
    [Abstract] [Full Text] [Related]

  • 35. Temporal changes in urinary excretion of liver-type fatty acid binding protein (L-FABP) in acute kidney injury model of domestic cats: a preliminary study.
    Katayama M, Miyazaki T, Ohata K, Oikawa T, Kamiie J, Sugaya T, Miyazaki M.
    J Vet Med Sci; 2019 Dec 26; 81(12):1868-1872. PubMed ID: 31645505
    [Abstract] [Full Text] [Related]

  • 36. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma.
    Teratani T, Domoto T, Kuriki K, Kageyama T, Takayama T, Ishikawa A, Ozono S, Nozawa R.
    Urology; 2007 Feb 26; 69(2):236-40. PubMed ID: 17320655
    [Abstract] [Full Text] [Related]

  • 37. Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.
    Ohata K, Sugaya T, Nguyen HN, Arai K, Hatanaka Y, Uno K, Tohma M, Uechi T, Sekiguchi K, Oikawa T, Nagabukuro H, Kuniyeda K, Kamijo-Ikemori A, Suzuki-Kemuriyama N, Nakae D, Noiri E, Miyajima K.
    Nephrology (Carlton); 2024 Mar 26; 29(3):117-125. PubMed ID: 37950597
    [Abstract] [Full Text] [Related]

  • 38. [Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease].
    Kamijo A, Sugaya T, Hikawa A, Kimura K.
    Rinsho Byori; 2003 Mar 26; 51(3):219-24. PubMed ID: 12707994
    [Abstract] [Full Text] [Related]

  • 39. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
    Am J Hypertens; 2007 Nov 26; 20(11):1195-201. PubMed ID: 17954367
    [Abstract] [Full Text] [Related]

  • 40. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.
    Sasaki H, Kamijo-Ikemori A, Sugaya T, Yamashita K, Yokoyama T, Koike J, Sato T, Yasuda T, Kimura K.
    Nephron Clin Pract; 2009 Nov 26; 112(3):c148-56. PubMed ID: 19390215
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.